| Imbruvica (ibrutinib) / AbbVie, J&J |
MCL-004, NCT02341781: Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment |
|
|
| Completed | N/A | 30 | US, Europe | | Celgene | Lymphoma, Mantle-Cell | 09/16 | 09/16 | | |
NCT02267590: Tissue Collection for Biomarkers Determining Resistance to Ibrutinib |
|
|
| Unknown status | N/A | 120 | Europe | | Royal Marsden NHS Foundation Trust, University Hospital Plymouth NHS Trust, Cambridge University Hospitals NHS Foundation Trust | Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia | 10/16 | 10/16 | | |
NCT02437019: Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
|
|
| Approved for marketing | N/A | | RoW | PCI-32765 (Ibrutinib) | Janssen-Cilag Farmaceutica Ltda. | B-cell Chronic Lymphocytic Leukemia | | | | |
| Unknown status | N/A | 40 | Europe | ibrutinib ou idelalisib | Institut Paoli-Calmettes, CHU de Reims | Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia | 07/18 | 07/18 | | |
NCT02582320: Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program |
|
|
| Completed | N/A | 264 | Europe | Ibrutinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia | 10/18 | 10/18 | | |
NCT01833039: An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
|
|
| Approved for marketing | N/A | | US, RoW | Ibrutinib | Janssen Biotech, Inc., Pharmacyclics LLC. | Relapsed or Refractory Mantle Cell Lymphoma | | | | |
NCT03502876: Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL |
|
|
| Completed | N/A | 198 | Europe | | French Innovative Leukemia Organisation | B Cell Chronic Lymphocytic Leukemia | 12/18 | 12/19 | | |
NCT03476655: Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India |
|
|
| Completed | N/A | 40 | RoW | Ibrutinib, IMBRUVICA | Johnson & Johnson Private Limited | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell | 05/19 | 05/19 | | |
| Unknown status | N/A | 50 | Europe | | Nantes University Hospital, Vendee Departmental hospital center | Gastrointestinal Microbiome | 08/19 | 08/20 | | |
| Completed | N/A | 88 | RoW | | Samsung Medical Center | Mantle Cell Lymphoma | 03/20 | 08/20 | | |
| Completed | N/A | 121 | Europe | Blood samples for pharmacokinetics exploration, Imagery, Quality of life scale, Detection of adverse events, Saliva samples, Blood sample, Biological statement, Clinical examination | University Hospital, Toulouse | Hematological Malignancies | 11/20 | 12/20 | | |
NCT04094051: Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice |
|
|
| Unknown status | N/A | 580 | RoW | Ibrutinib | The First Affiliated Hospital with Nanjing Medical University, Xian-Janssen Pharmaceutical Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/20 | 12/21 | | |
LLC1618, NCT03528941: The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib |
|
|
| Completed | N/A | 109 | Europe | Lamivudine, No prophylaxis | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia | 03/21 | 06/21 | | |
NCT04852692: A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants |
|
|
| Terminated | N/A | 15 | RoW | | Janssen Korea, Ltd., Korea | Chronic Graft vs Host Disease | 08/21 | 08/21 | | |
NCT04016636: A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia |
|
|
| Completed | N/A | 50 | RoW | Standard of Care | Mela Osorio Maria Jose, Janssen-Cilag Ltd. | CLL | 08/21 | 10/22 | | |
IOSI-EMA-001, NCT02827617: Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia |
|
|
| Completed | N/A | 56 | Europe | Ibrutinib, PCI-32765 | Oncology Institute of Southern Switzerland | Chronic Lymphocytic Leukemia | 08/21 | 05/24 | | |
| Unknown status | N/A | 70 | RoW | | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Chronic Lymphocytic Leukemia | 09/21 | 04/22 | | |
CR108517, NCT03720561: A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting |
|
|
| Completed | N/A | 312 | Europe | Ibrutinib | Janssen-Cilag S.p.A. | Leukemia, Lymphocytic, Chronic, B-Cell | 11/21 | 11/21 | | |
| Recruiting | N/A | 60 | Europe | | European Georges Pompidou Hospital | Leukemia, Chronic Lymphatic, Mantle Cell Lymphoma | 05/22 | 11/22 | | |
| Completed | N/A | 319 | Europe, RoW | Ruxolitinib, Extracorporeal photopheresis, Ibrutinib | European Society for Blood and Marrow Transplantation, Mallinckrodt | Steroid Refractory GVHD | 06/22 | 06/22 | | |
FIRE, NCT03425591: A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice |
|
|
| Completed | N/A | 508 | Europe | Ibrutinib | Janssen-Cilag Ltd. | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell | 08/22 | 08/22 | | |
| Active, not recruiting | N/A | 36 | Europe | Ibrutinib | IRCCS San Raffaele | PCNSL | 01/23 | 08/26 | | |
| Completed | N/A | 40 | RoW | | University Hospital "Sestre Milosrdnice" | Atrium; Beat, Echocardiography, Physiology, Therapy Adverse Effect | 03/23 | 03/23 | | |
NCT04694560: A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
|
|
| Withdrawn | N/A | 0 | US | Treatment Free Observation | Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC. | CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 03/23 | 03/23 | | |
| Completed | N/A | 152 | Europe | | French Innovative Leukemia Organisation, Bristol-Myers Squibb | CLL, Relapsed, CLL, Refractory, Bruton Tyrosine Kinase Inhibitor, Small Lymphocytic Leukemia | 12/23 | 03/24 | | |
NCT06224452: Is Ibrutinib-related Atrial Fibrillation Dose Dependent |
|
|
| Not yet recruiting | N/A | 18000 | Europe | ibrutinib exposure | University Hospital, Caen | Hematological Malignancy, Atrial Fibrillation | 05/24 | 07/24 | | |
QOLIBRI, NCT06299540: Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 180 | Europe | Individual Physical Activity Intervention (IPAI), Ibrutinib | Janssen Cilag S.A.S. | Leukemia, Lymphocytic, Chronic, B-Cell | 09/26 | 10/27 | | |
NCT06561243: Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies |
|
|
| Active, not recruiting | N/A | 15000 | Europe | BTK inhibitor (Ibrutinib or Acalabrutinib) | University Hospital, Caen | Chronic B-cell Malignancies, BTK Inhibitors, Cardiovascular Diseases | 09/24 | 10/24 | | |
NCT04938141: MEOI and HRQoL in CLL Patients Treated With BTKis |
|
|
| Completed | N/A | 23 | US | | AstraZeneca | Chronic Lymphocytic Leukemia | 09/24 | 09/24 | | |
| Not yet recruiting | N/A | 525 | | Nil | the First Affiliated Hospital of Army Medical University, PLA; the First Affiliated Hospital of Army Medical University, PLA, National Natural Science Foundation of China for Excellent Young Scholars (81922056), Chongqing Academician in Chongqing Leading Science and Technology Innovation Guidance Project (STC2020YSZX-JCYJX00 | glioma | | | | |
NCT05360758: Ibrutinib Adapted to Response in Patients With CLL |
|
|
| Not yet recruiting | N/A | 80 | NA | Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia | Grupo Argentino de Tratamiento de la Leucemia Aguda | Chronic Lymphocytic Leukemia | 06/25 | 12/25 | | |
CLL2523, NCT06084923: Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression |
|
|
| Not yet recruiting | N/A | 73 | NA | Observation | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia | 05/26 | 05/26 | | |
| Withdrawn | N/A | 160 | NA | Electrocardiogram, ECG, Echocardiogram, TTE, Cardiac magnetic resonance imaging, Cardiac MRI, Mobile cardiac telemetry, Mobile telemetry, Blood pressure monitoring, Home blood pressure monitoring, Blood draw | Dana-Farber Cancer Institute, AstraZeneca | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/26 | 01/28 | | |
| Recruiting | N/A | 100 | Europe | ophthalmological examination, blood test | Centre Hospitalier Universitaire Dijon | Ibrutinib Treatment | 03/27 | 03/27 | | |
